环孢多肽(cyclosporine)是用于接受肾、肝、心、心-肺和骨髓移植的病人的主要免疫抑制剂。据报道,肾脏移植患者有12～40％因急性肾小管坏死需要透析,约10％肝脏移植患者由于手术并发症或药物毒性而需血液透析。现已知血液透析可以加快某些药物的清除,本文研究的目的在于测定环孢多肽经血液透析清除的程度和患者透析后是否需要补充环孢多肽。研究对象为5名成年肝脏移植者,他们均需要血液透析防止术后肾功能衰竭。患者 Cyclosporine is the primary immunosuppressant used in patients receiving kidney, liver, heart, heart-lung and bone marrow transplants. It has been reported that 12-40% of kidney transplant patients require dialysis due to acute tubular necrosis and about 10% of liver transplant patients require hemodialysis due to surgical complications or drug toxicity. It is known that hemodialysis can speed up the clearance of certain drugs. The purpose of this study was to determine the extent of clearance of cyclosporin by hemodialysis and whether patients need cyclosporin supplementation after dialysis. The subjects were five adult liver transplanters who all needed hemodialysis to prevent postoperative renal failure. patient